The KCCOP is a consortium of 6 hospitals, 7 affiliated physician offices, and 21 investigators--representing a resource of 2,385 hospital beds. We have successfully operated for three years as a CCOP with a Central Operations Committee overseeing all scientific activities. The Operations Office, located at fiscal agent Baptist Memorial Hospital, provides centralized support and data management procedures. All units have clearly defined roles and formalized operating procedures, and a strong quality control element. The KCCOP will continue to serve the same 8-county SMSA with a population of over 1.3 million. Of the 5,071 new cancer patients projected for 1986, 2,740 of these patients will be seen at member institutions. Black and Hispanic residents comprise 15-20% of this population. We have a long-standing record of community involvement in oncologic research and the 6 component hospitals have 900 affiliated physicians. The hospitals have joint disease site committees, patient management guidelines, oncology nursing committees, policies, procedures, IRB's, and data management support. KCCOP has had a formal quality control plan since its inception and a good record for data quality (only 3 of 261 patient registrations have been judged ineligible and numerous data reviews ensure completeness and accuracy). In the past 3 years, KCCOP investigators have placed 261 patients on clinical protocols, an average accrual rate of 87 patients per year. KCCOP currently manages more than 100 active protocols from three research bases: SWOG, RTOG, and M.D. Anderson. We project to achieve 67 SWOG accrual credits, 14 RTOG, and 46 MDA in Year 05. Our record of cancer control activities is lengthy having previously developed a five-hospital cooperative hospice, joint patient management guide-lines, joint site and specialty committees, outreach, professional and patient education, pain clinics, screening programs, etc.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035176-05
Application #
3557569
Study Section
(SRC)
Project Start
1983-09-15
Project End
1990-05-31
Budget Start
1988-06-01
Budget End
1989-05-31
Support Year
5
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Baptist Medical Center
Department
Type
DUNS #
City
Kansas City
State
MO
Country
United States
Zip Code
64131
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Philip, Philip A; Goldman, Bryan; Ramanathan, Ramesh K et al. (2014) Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO Cancer 120:2980-5
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7

Showing the most recent 10 out of 147 publications